Jafar Kafaie, MD
Neurology · Paramus, NJNPI 1467616094
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,438 of the $1,553 with a category attached, or 92.6%. Argenx US, Inc. accounts for 92.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,438 and has fallen 98.9% since, to $16 in 2024. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 8 payments — averaging $194.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$1K
- Philips North America LLC$73
- Johnson & Johnson$26
- Pfizer$16
Across 20 payments — averaging $4288.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$35K
- Alkermes, Inc.$23K
- AstraZeneca$16K
- Novartis$11K
What the payments were for
- Consulting fees$1,43893%
- Food & beverage$1157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 1 | $1,438 |
| Philips North America LLC | 4 | $73 |
| Johnson & Johnson | 2 | $26 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,438
How this compares
$1,553 in reported general payments places this provider in the 45th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 27 | $2,162 |
| Gabapentin | 74 | $1,324 |
| Pregabalin | 61 | $1,286 |
| Duloxetine Hcl | 33 | $1,025 |
| Pyridostigmine Bromide | 23 | $906 |
| Prednisone | 88 | $555 |
| Amitriptyline Hcl | 29 | $441 |
| Baclofen | 12 | $387 |
| Topiramate | 23 | $280 |
Paid to pharmacies, not to this prescriber.
Other neurology in Paramus
- Yeva FernandezParamus$67K
- Eric MittelmannParamus$41K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.